2022 University of Washington $50000.00 Phase 1 Technology Commercialization Grant: Craven

Phase 1 Technology Commercialization Grant: Rapid identification of in cellulo active cyclic-peptides inhibiting ‘undruggable’ targets requiring sub-type binding specificity